Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

938
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
938
Vaccinations01:51

Vaccinations

52.0K
Overview
52.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunogenicity of PCV13 during Hospitalization soon after infection resolution: Vaccis study.

NPJ vaccines·2026
Same author

Hepatitis B Virus, Pneumococcal, Diphtheria, and Tetanus Vaccination Responses in Compensated Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Aqueous Continuous Flow Synthesis of Cadmium Chalcogenide Quantum Dots: Opportunities and Challenges.

JACS Au·2026
Same author

Microbiota insights in endometriosis.

Microbiome·2025
Same author

The genetic landscape of frontotemporal lobar degeneration: investigation of a diagnostic cohort of 2747 probands.

Brain : a journal of neurology·2025
Same author

Evaluation of a Multiplex Electrochemiluminescence Assay for Detection of Anti-Pneumococcal Antibodies in the Diagnosis of Selective Polysaccharide Antibody Deficiency.

Journal of clinical immunology·2025

Related Experiment Video

Updated: Feb 19, 2026

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

13.3K

[Focus on evaluating the pneumococcal vaccine response].

Guillaume Petit1, Camillia Belhoul1, Antoine Dinard1

  • 1Université Paris Cité, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, Service d'immunologie biologique, 75679 Paris, France.

Annales De Biologie Clinique
|February 17, 2026
PubMed
Summary

Pneumococcal conjugate vaccines (PCV) offer improved protection against invasive infections, especially in children. Evaluating vaccine response requires measuring specific IgG by ELISA and antibody function via opsonophagocytosis (OPA) tests for optimal public health strategies.

Keywords:
ELISAOPApneumococcal vaccinevaccine response

More Related Videos

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.7K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.3K

Related Experiment Videos

Last Updated: Feb 19, 2026

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

13.3K
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.7K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.3K

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • Streptococcus pneumoniae causes invasive infections with high morbidity and mortality, particularly in vulnerable populations.
  • The bacterial polysaccharide capsule is a key virulence factor and target for pneumococcal vaccines, with serotypes defining vaccine efficacy.
  • Existing vaccines include PPV-23 and conjugate vaccines (PCV), with PCV-21 representing the latest generation offering broader serotype coverage.

Purpose of the Study:

  • To outline the World Health Organization (WHO) recommended methods for evaluating pneumococcal vaccine response.
  • To detail the established thresholds for protective immunity using ELISA and opsonophagocytosis (OPA) assays.
  • To emphasize the need for updated vaccination recommendations and expanded response evaluations due to evolving vaccine epidemiology.

Main Methods:

  • Quantification of serotype-specific IgG antibodies using Enzyme-Linked Immunosorbent Assay (ELISA).
  • Assessment of antibody functionality through the opsonophagocytosis (OPA) test.
  • Defined protective thresholds for ELISA (1 μg/mL in adults, 0.35 μg/mL in children) and OPA (exceeding laboratory-defined LOQ).

Main Results:

  • Protective vaccine immunity is achieved when ELISA thresholds are met for at least 70% of tested serotypes (50% in children).
  • OPA response is considered protective if the opsonization index exceeds the limit of quantification (LOQ) for at least 70% of serotypes.
  • New vaccine introductions necessitate regular updates to vaccination strategies and response assessments.

Conclusions:

  • Comprehensive evaluation of pneumococcal vaccine response involves both IgG quantification (ELISA) and functional antibody assessment (OPA).
  • Established thresholds provide benchmarks for protective immunity in different age groups.
  • Adapting vaccine recommendations and evaluation methods is crucial to address the changing landscape of pneumococcal disease epidemiology.